Compare DexCom, Inc. (DXCM) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Neurocrine Biosciences Inc — how do they compare? DexCom, Inc. trades at $89.2 (market cap $33.79B), while Neurocrine Biosciences Inc trades at $152.14 (market cap $16.46B). The key difference: DexCom, Inc. is far larger — about 2.1× Neurocrine Biosciences Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| DXCM | NBIX | |
|---|---|---|
Market Cap | $33.79B | $16.46B |
Sector | Health | Health |
52-Week High | $89.53 | $185.50 |
52-Week Low | $54.84 | $123.10 |
Enterprise Value | $33.24B | $16.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
